Long-term study of ustekinumab for Crohn's and colitis
Part of Digestive system clinical trials.
This study follows patients with Crohn's disease or ulcerative colitis who started taking ustekinumab between February 2019 and March 2021, to see how well it works over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Diagnosed with Crohn's disease or ulcerative colitis
- Started treatment with ustekinumab between February 2019 and March 2021
- Willing to sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows adults with Crohn’s disease or ulcerative colitis to compare the long-term safety of ustekinumab against other biologic medicines. It may help show how safe these treatments are over time, using medical records.
This study looks at how well Ustekinumab (Stelara) works for Crohn's disease in people who started the medication in 2024. Researchers want to understand its real-world benefits and safety.
This Phase 1 study uses a special camera to track how ustekinumab (a common biologic medicine) spreads in inflamed tissue. It aims to help researchers understand where the drug goes in Crohn’s disease and psoriasis, especially when standard treatments haven’t worked.
This trial tests whether a combination of two drugs (upadacitinib and ustekinumab) works better than a higher dose of ustekinumab alone for people with active Crohn's disease that hasn't responded well to previous treatments.
This study tests a new treatment for people with Crohn's disease who have lost response to ustekinumab (Stelara). It aims to see if a different dosing or additional treatment can help regain control of symptoms.
This study looks at whether guselkumab, a different biologic medicine, can help people with Crohn's disease who have already tried ustekinumab but it didn't work well or caused side effects. It aims to see if switching to guselkumab is safe and effective.
Hear when a new IBD - Inflammatory Bowel Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.